HSPA5 and cancer: One the other hand, small molecule GRP78 inhibitors, in principle, should be able to inhibit GRP78 activity in all the intracellular compartments, as well as on the cell surface, thus simultaneously shutting down the multitude of pro-growth and pro-survival pathways regulated by GRP78, making it more difficult for cancer cells to develop resistance to anti-GRP78 therapy.